Note: The following is an excerpt from a press release from Novo Nordisk. Read the full press release here.Â
Novo Nordisk, a global healthcare company, today announced that Rebinyn, Coagulation Factor IX (Recombinant), GlycoPEGylated, is now available in the United States for the treatment of hemophilia B.
Rebinyn is an extended half-life injectable medicine used to treat and control bleeding in adults and children with hemophilia B. It can be used to treat bleeds when they occur and to help manage bleeding during surgery. Rebinyn is not for routine prophylaxis (regular infusions to prevent bleeding) or for immune tolerance induction (treatment of inhibitors) in patients with hemophilia B.
Hemophilia B is a serious, chronic, inherited bleeding disease that affects about 5,000 people in the U.S. People living with hemophilia B have low levels of clotting Factor IX protein in the blood, often resulting in prolonged or spontaneous bleeding, especially into the muscles, joints or internal organs. Rebinyn replaces the clotting Factor IX that people with hemophilia B are missing.
In phase 3 studies, a single dose of Rebinyn 40 IU/kg in adults was shown to elevate factor activity above baseline levels by 94 percent and sustain average factor levels of 17 percent seven days post-dose. Adults also achieved an 83-hour average half-life after receiving a single infusion of Rebinyn.
Read the full press release here.
Please note that HFA does not recommend, endorse or make any representation about the efficacy, appropriateness or suitability of any specific products, treatments, or opinions. Please consult your physician before use of any treatments.
